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Characterization of two distinct 
early post-entry blocks to HIV-1 in 
common marmoset lymphocytes
Beatriz Pacheco1,2,†, Luis Menéndez-Arias1 & Joseph Sodroski2,3
In nature, primate lentiviruses infect humans and several Old World monkeys and apes. However, to 
date, lentiviruses infecting New World monkeys have not been described. We studied the susceptibility 
of common marmoset cells to HIV-1 infection and observed the presence of post-entry blocks to the 
early phase of HIV-1 infection in peripheral blood lymphocytes (PBLs) and a B lymphocytic cell line  
(B-LCL). The blocks present in these cells are dominant and phenotypically different from each other. In 
PBLs, the block occurs at the level of reverse transcription, reducing the accumulation of early and late 
transcripts, similar to the block imposed by TRIM5α. However, we have found that marmoset TRIM5α 
does not block HIV-1. In contrast, the restriction factor present in B-LCLs blocks HIV-1 replication at 
a later step, after nuclear entry, and inhibits integration. Additionally, we have identified an HIV-1 
capsid mutant, N74D, that is able to escape the restriction in the marmoset B-LCLs. Our results suggest 
that the factors responsible for the blocks present in marmoset PBLs and B-LCLs are different. We 
propose the existence of at least two new restriction factors able to block HIV-1 infection in marmoset 
lymphocytes.
During evolution, host species have developed as part of their intrinsic immune system dominant-acting fac-
tors (known as restriction factors) that can block replication of viruses, including retroviruses. In response, 
the targeted viruses have evolved countermeasures to avoid restriction by these factors. This continuous 
host-versus-virus battle has led to the speciation of viruses.
The primate lentiviruses include the human immunodeficiency viruses type 1 and 2 (HIV-1 and HIV-2, 
respectively), and more than 40 different lentiviruses, collectively denominated simian immunodeficiency viruses 
(SIVs), that infect several species of Old World monkeys and apes of Africa. In nature, HIV-1 and HIV-2 infect 
humans, while HIV-1-related SIVcpz and SIVora viruses infect chimpanzees and orangutans, respectively, and other 
SIV variants infect Old World monkeys1.
Some of the restriction factors that limit lentivirus host range have been described including TRIM5α , 
SAMHD1, MX2, BST2, and APOBEC3G (A3G)2–10. TRIM5α acts at an early post-entry step of the viral life cycle, 
recognizing the incoming viral capsid in a species-specific way and inducing accelerated uncoating of the cap-
sid9,11. The main consequence of this recognition is a reduced accumulation of reverse transcription products that 
results in an abortive infection9,12. The cellular protein SAMHD1, a dendritic- and myeloid-cell-specific HIV-1 
restriction factor, inhibits the viral life cycle at the reverse transcription step and is counteracted by the viral pro-
tein Vpx3,5. MX2 has been defined as a potent inhibitor of the early phase of HIV-1 infection2,4,6. The capsid region 
of the Gag protein dictates susceptibility to MX2, and the block to infection affects both nuclear accumulation 
and integration of the viral DNA. A3G is a member of the cytidine deaminase family that when incorporated into 
the virions can block replication at early post-entry steps of the viral cycle by various mechanisms8. By contrast, 
BST2 blocks replication at late steps in the viral cycle, inhibiting the release of the viral particles7,10. Several lines 
of evidence suggest the existence of additional restriction factors that block replication of lentiviruses.
New World monkeys are apparently resistant to infection by known lentiviruses. Some of the blocks to HIV-1 
infection in common marmosets, a New World monkey, have been characterized. The earliest block to HIV-1 
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infection of common marmoset cells occurs at the level of virus entry, due to an inefficient recognition of com-
mon marmoset CD4 and CCR5 by the HIV-1 envelope glycoproteins13. Common marmoset A3G and BST2 also 
block HIV-1 replication14. Using a directed evolution method that takes advantage of the natural ability of the 
virus to mutate during replication, we have generated HIV-1 variants able to replicate in cells expressing common 
marmoset CD4 and CXCR415, A3G or BST214.
Here, we report the existence of two additional post-entry blocks in common marmoset primary lymphocytes 
and a B lymphocytic cell line (B-LCL). The blocks present in these cells are dominant and phenotypically different 
from each other. We identified an HIV-1 capsid mutant that is able to escape the block in the marmoset B-LCLs. 
We propose the existence of at least two restriction factors able to block HIV-1 infection in these cells. This work 
provides new insights into virus-host interactions. Understanding how these restriction factors operate and how 
the virus is able to escape from these blocks in different species could assist the development of novel interven-
tions against HIV-1 infection.
Results
Post-entry block(s) to HIV-1 in common marmoset peripheral blood lymphocytes. Common 
marmosets are resistant to HIV-1 infection due to the presence of several barriers13,14. To investigate the pres-
ence of additional early blocks to HIV-1 infection in primary lymphocytes of common marmosets, we prepared 
single-cycle luciferase reporter viruses pseudotyped with the vesicular stomatitis virus G (VSV-G) envelope gly-
coprotein in 293T cells. These HIV-1 reporter viruses were used to challenge phytohemagglutinin (PHA-P)-
activated peripheral blood lymphocytes (PBLs) from humans or common marmosets. As shown in Fig. 1A, in the 
marmoset PBLs, the infectivity of HIV-1 was more than 10-fold lower than in the human PBLs, suggesting the 
presence of a post-entry block in the marmoset PBLs.
The recombinant viruses used to test HIV-1 infectivity in PBLs were pseudotyped with VSV-G, which has 
been shown to mediate viral entry through clathrin-based endocytosis16–18. To evaluate whether the block to 
HIV-1 infection was envelope dependent, we prepared HIV-1 viruses pseudotyped with the amphotropic 
murine leukemia virus (A-MLV) envelope glycoprotein, which mediates viral entry through a mechanism that 
involves caveola-dependent endocytosis or macropinocytosis19,20. The infectivity of the viruses pseudotyped 
with the A-MLV envelope glycoprotein was lower in all the cells compared with VSV-G-pseudotyped viruses, 
probably due to the slower entry kinetics of the A-MLV envelope19. Nonetheless, with the A-MLV-pseudotyped 
viruses the strength of the blocks to HIV-1 infection in marmoset PBLs were similar to those observed with 
VSV-G-pseudotyped viruses (Fig. 1B). These results indicate that an early-phase block to HIV-1 infection exists 
in marmoset PBLs unrelated to the route of entry of the virus.
A block to HIV has been described in quiescent T cells21. One explanation of the low infectivity of HIV-1 in 
the marmoset PBLs is that the cells were not properly activated. However, we observed that with our activation 
protocol and under the cell culture conditions used in our assays, the marmoset PBLs proliferate efficiently, even 
better than the human PBLs. To quantitate the efficiency of proliferation of the human and marmoset PBLs we 
used a CellTrace® Violet cell proliferation kit (Invitrogen). This dye readily diffuses into cells and binds cellular 
amines resulting in a stable, well-retained fluorescent label. With each cycle of proliferation the fluorescence sig-
nal in the cells will decrease. The decrease in fluorescence over time in the marmoset PBLs was more pronounced 
than in the human PBLs (Fig. S1). This result indicates that the marmoset PBLs proliferated more efficiently than 
the human PBLs, and argues against the possibility that the observed block was due to insufficient activation of 
the marmoset PBLs.
Figure 1. Post-entry block to HIV-1 in common marmoset PBLs. Infectivity of recombinant HIV-1 viruses 
expressing luciferase and pseudotyped with VSV-G (A) or A-MLV (B) envelope glycoproteins for PBLs from 
humans (hu) or common marmosets (mar). Forty-eight hours after the viruses were added to the PBLs, the 
infectivity of the viruses was determined by measuring the relative luciferase activity (RLU, relative luciferase 
units) in the cells. The charts show the results of four (A) or two (B) independent experiments and the means. 
Reported p-values (2-tailed) were obtained with an unpaired t-test.
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Post-entry block to HIV-1 in marmoset B lymphocytic cell lines. We tested a marmoset B lympho-
cytic cell line (B-LCL) to evaluate whether a block to HIV-1 infection similar to that found in marmoset PBLs 
is present in this cell line. Human and marmoset B-LCLs were challenged with single-cycle HIV-1 luciferase 
reporter viruses pseudotyped with VSV-G. Marmoset B-LCLs exhibited a greater than 10-fold reduction in the 
infectivity of HIV-1 compared to that in human B-LCLs (Fig. 2A), reminiscent of the results obtained in PBLs. 
We also found that the infectivity of SIVmac was reduced more than 100-fold in the marmoset B-LCLs compared 
to that in human B-LCLs (Fig. 2A). Similarly, the infectivity of HIV-1 viruses pseudotyped with the A-MLV enve-
lope glycoprotein was also more than 10-fold lower in the marmoset B-LCLs than in the human B-LCLs (Fig. 2B). 
These results indicate the existence of a specific block to HIV-1 as well as to SIVmac in the marmoset B-LCLs.
The post-entry blocks to HIV-1 in marmoset PBLs and B-LCLs are dominant. To determine 
whether the block to HIV-1 infection in marmoset PBLs was due to the presence of a dominant factor and not to 
a deficiency in a factor needed for HIV-1 replication, we prepared heterokaryons and homokaryons of restricted 
and unrestricted PBLs using polyethylene glycol (PEG). As a control, we also prepared mixtures of human and 
marmoset PBLs that were not treated with PEG in parallel, and tested the infectivity of HIV-1 in the PEG-fused 
and non-fused cell mixtures. If the block were due to the presence of a dominant factor, we would expect to 
observe low HIV-1 infectivity in heterokaryons formed between restricted (marmoset) and unrestricted (human) 
cells. On the contrary, if the block were due to the absence of a factor needed for HIV-1 infection, we would expect 
to see HIV-1 infectivity at levels close to those seen in unrestricted cells or in the non-fused human-marmoset 
cell mixtures. As shown in Fig. 3A, HIV-1 infectivity was reduced in heterokaryons formed between human 
and marmoset PBLs by 2.6-fold compared to human-human homokaryons. We did not observe a significant 
reduction in infectivity in the non-fused human-marmoset cell mixtures (Fig. 3A, right). These results suggest 
that the early block to HIV-1 present in marmoset PBLs is most likely due to the presence of a dominant-acting 
factor, as is the case of the block present in rhesus cells22. The block in human-marmoset heterokaryons was not 
as pronounced as in marmoset-marmoset homokaryons, which showed a 12-fold lower infectivity compared to 
human-human homokaryons. This effect can be attributed to the formation of some human-human homokary-
ons and/or to incomplete cell-cell fusion. We have not been able to assess the efficiency of heterokaryon formation 
in our infection experiments because treatment of the cells with dyes that would allow this measurement resulted 
in background levels of infectivity in the PEG-treated cells. However, in pilot experiments using Vibrant DiO and 
Dil cell labeling solutions (Molecular Probes) to evaluate cell-cell fusion, the efficiency of heterokaryon formation 
ranged from 60% to 80%. Thus, it is likely that most cells have fused under the conditions of our experiment.
To evaluate whether the block present in the marmoset B-LCLs was also caused by a dominant factor, we 
prepared heterokaryons and homokaryons of marmoset and human B-LCLs. As a control, we also prepared 
mixtures of human and marmoset B-LCLs that were not treated with PEG in parallel. We challenged the 
PEG-fused cells and the non-fused mixtures with HIV-1 luciferase reporter viruses pseudotyped with VSV-G. 
The human-marmoset heterokayons (PEG-treated cells) exhibited a reduced permissivity (7-fold decrease) to 
HIV-1 compared with the human-human homokaryons (Fig. 3B, left). However, we didn’t observe a substantial 
reduction in HIV-1 infectivity in the human-marmoset B-LCLs mixtures that had not been treated with PEG 
(Fig. 3B, right). These results suggest that the block to HIV-1 infection in the marmoset B-LCLs is due to a dom-
inant factor, not to the lack of a factor needed for HIV-1 infection.
Figure 2. Post-entry block to HIV-1 in common marmoset B-LCLs. Human (hu) or marmoset (mar) B-LCLs 
were challenged with HIV-1 or SIVmac luciferase reporter viruses pseudotyped with VSV-G (A) or the A-MLV 
envelope glycoprotein (B). Forty-eight hours later, the infectivity of the viruses was determined by measuring 
the relative luciferase activity (RLU) in the B-LCLs. The charts show the results of four (A) or three  
(B) independent experiments. Reported p-values (2-tailed) were obtained with an unpaired t-test.
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The post-entry block to HIV-1 in marmoset PBLs reduces accumulation of early and late reverse 
transcription products. When complemented in trans with VSV-G, the single-cycle reporter viruses used 
in our experiments are able to enter the target cells. If the cells are permissive to infection, the virus will be able 
to complete all the early events in the replication cycle, including reverse transcription, nuclear entry, integration 
and reporter gene expression, but will not produce new viral particles. To define the step of the early HIV-1 repli-
cation cycle that is blocked in marmoset PBLs, we challenged human or marmoset PBLs with single-cycle HIV-1 
green fluorescent protein (GFP) reporter viruses pseudotyped with VSV-G and analyzed the formation of early 
and late reverse transcription (RT) products by real-time qPCR at different times post-infection. As a control, we 
also infected human and marmoset PBLs with viruses lacking an envelope glycoprotein (Δ Env). As expected, 
in human PBLs we detected an increase of early and late RT products over time (Fig. 4). On the contrary, in 
Figure 3. The post-entry block(s) to HIV-1 in marmoset PBLs and B-LCLs are dominant.  
(A) Heterokaryons or homokaryons of human (hu) and marmoset (mar) PBLs were produced by treatment 
with PEG. As a control, mixtures of human and marmoset cells were treated the same way but without 
adding PEG. The fused and non-fused cell mixtures were challenged with HIV-1 luciferase reporter viruses 
pseudotyped with VSV-G. Forty-eight hours later, the infectivity of the viruses was determined by measuring 
the relative luciferase activity in the cells. The infectivity in the human-human homokaryons is normalized to 
100%, and the relative infectivity in the other homo-heterokaryons is shown. The results of four (+ PEG) and 
two (no PEG) independent experiments and their means are shown. (B) Human and marmoset B-LCLs were 
fused with PEG to generate hetero- or homokaryons. As a control, mixtures of human and marmoset cells were 
treated the same way but without adding PEG. The fused and non-fused cell mixtures were challenged with 
HIV-1 luciferase reporter viruses pseudotyped with VSV-G. Forty-eight hours later, the infectivity of the viruses 
was determined by measuring the relative luciferase activity in the cells. The infectivity in the human-human 
homokaryons is normalized to 100%, and the relative infectivity in the other homo-heterokaryons is shown. 
The results of three independent experiments and their means are shown. Reported p-values (2-tailed) were 
obtained with an unpaired t-test.
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marmoset PBLs, the amounts of early and late RT products exhibited slight decreases over time (Fig. 4). These 
observations suggest that the factor responsible for the HIV-1 block in marmoset PBLs acts at an early step after 
virus entry, before or during reverse transcription. This factor may directly or indirectly disrupt the reverse tran-
scription process itself or degrade the products of reverse transcription.
TRIM5α and TRIMCyp are not responsible for the early block to HIV-1 in marmoset PBLs. The 
early post-entry block to HIV-1 infection in marmoset PBLs resembles the early block imposed by TRIM5α 
and TRIMCyp in some species9,23. To test whether TRIM5α from the common marmoset accounted for the 
observed block to HIV-1, we cloned marmoset TRIM5α (marTRIM5α ) and prepared stable cell lines expressing 
this protein. The expression of the HA-tagged marmoset TRIM5α in Cf2Th cells was documented by Western 
blot (data not shown). The infectivity of HIV-1 and SIVmac in these stable cell lines was tested with single-cycle 
luciferase reporter viruses. We observed only minimal differences (about a 1.7-fold decrease) in the infectivity of 
HIV-1 in cells expressing marTRIM5α compared to control cells transduced with the empty vector (Fig. 5A, left), 
suggesting that marTRIM5α does not efficiently block HIV-1. However, we observed that marTRIM5α was able 
to strongly block SIVmac infection (Fig. 5A, right), which confirms that marTRIM5α is active in these cell lines.
The TRIMCypA gene is the result of a retrotransposition of a CypA gene into the TRIM5 gene in some monkey 
species. The encoded protein TRIMCyp has been shown to have antiviral activity against some retroviruses24–28. 
A CypA retrogene has not been found proximal to or downstream of TRIM5 in marmosets29 and our attempts to 
amplify a TRIMCypA cDNA from common marmoset mRNA were unsuccessful. To rule out TRIMCypA or a 
CypA-containing protein as a potential factor responsible for the early post-entry block in marmoset PBLs, we 
carried out the infection of PBLs from five common marmosets in the presence or absence of cyclosporine A 
(CsA), a drug that binds CypA and inhibits its binding to the HIV-1 capsid. As shown in Fig. 5B, treatment with 
CsA reduced the infectivity of HIV-1 in human PBLs, as previously reported30. Similarly, treatment with CsA 
Figure 4. The post-entry block to HIV-1 in marmoset PBLs reduces the accumulation of early and late 
reverse transcription products. Human (hu) or marmoset (mar) PBLs were challenged with single-cycle 
HIV-1 viruses pseudotyped with VSV-G pretreated with DpnI for 1 h. As a control, cells were also challenged 
with viruses lacking an envelope glycoprotein (Δ Env). Two hours post-infection, the cells were thoroughly 
washed 3 times with PBS to remove excess virus. At different time points after infection, cells were collected 
and total DNA isolated. The amounts of early and late RT products were quantified by real-time qPCR using 
TaqMan® chemistry. The results of two independent experiments are shown.
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significantly reduced the infectivity of HIV-1 in marmoset PBLs, suggesting that the early block in marmoset 
PBLs was not due to the action of TRIMCyp or other similar protein containing CypA. On the contrary, our 
results suggest that CypA contributes to the infectivity of HIV-1 in human and marmoset PBLs. In contrast, 
in rhesus macaque PBLs, addition of CsA slightly increased the infectivity of HIV-1, an effect that could be 
due to the presence of TRIMCyp in this rhesus macaque24,25,27,28 or may reflect the contribution of CypA to 
TRIM5α -mediated restriction.
The post-entry block to HIV-1 in marmoset B-LCLs acts at a step after reverse transcription. 
Our results indicated that a post-entry block to HIV-1 infection exists in marmoset B-LCLs. To evaluate whether 
this block resembles the one observed in the marmoset PBLs, we analyzed by real-time qPCR the formation of 
early and late RT products at different time points after the infection of B-LCLs with HIV-1 single-cycle GFP 
reporter viruses. Surprisingly, the results in the B-LCLs did not recapitulate the results obtained in marmoset 
PBLs. In marmoset B-LCLs, the formation of early and late RT products was considerably higher than in human 
B-LCLs (Fig. 6A and B), in contrast with the data obtained in the PBLs (Fig. 4). These results indicated that the 
Figure 5. Effect of TRIM5α and cyclosporine A on the infectivity of HIV-1. (A) Cf2Th cell lines stably 
expressing marmoset TRIM5α with an HA tag, were challenged with single-cycle HIV-1 (left) or SIVmac 
(right) luciferase reporter viruses. Forty-eight hours post-challenge, the infectivity of the HIV-1 viruses was 
determined by measuring the relative luciferase activity (RLU) in the cells. Data shown are the means  
± standard deviations of three independent experiments. (B) Human, rhesus macaque or common marmoset 
PBLs were challenged with single-cycle HIV-1 viruses pseudotyped with VSV-G in the presence or absence 
of 5 μ M cyclosporine A (CsA). PBLs from five different common marmoset donors were tested. Forty-eight 
hours post-challenge, the infectivity of the HIV-1 viruses was determined by measuring the relative luciferase 
activity (RLU) in the cells. Reported p-value (2-tailed) for the 5 common marmoset PBLs (untreated versus CsA 
treated) were obtained with a paired t-test.
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Figure 6. HIV-1 is blocked in marmoset B-LCLs after reverse transcription. Human (hu) or marmoset (mar) 
B-LCLs were challenged with single-cycle HIV-1 GFP reporter viruses pseudotyped with VSV-G (indicated as 
WT), or as a control with viruses lacking an envelope glycoprotein (Δ Env). Viruses were pretreated with  
DNase I for 1 h. Two hours post-infection (p.i.), the cells were thoroughly washed 3 times with PBS. At different 
time points after infection, cells were collected and total DNA isolated. The amounts of early (A) and late  
(B) RT products and 2-LTR circles (C) were quantified by real-time qPCR using TaqMan® chemistry. ND, not 
detectable. The results of two independent experiments are shown.
www.nature.com/scientificreports/
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factor responsible for the block to HIV-1 in the marmoset B-LCLs was acting after reverse transcription. We 
attempted to measure integration of the proviral DNA with the Alu-PCR assay31. However, we were unable to 
amplify any viral DNA in the infected human or marmoset B-LCLs with this test. As a surrogate of Alu PCR to 
measure the integration of viral DNA, we quantified the amount of proviral DNA six or seven days after infection, 
using the same primers as those used for the late RT assay. At this time point, all the viral DNA remaining in the 
cells should be integrated in the genome32. Although at early time points the amount of viral DNA was higher in 
the marmoset than in the human cells, after 24 hours in culture we observed a substantial drop in the amount of 
viral DNA in the marmoset B-LCLs; at six/seven days post-infection, the amount of viral DNA in the marmoset 
B-LCLs was lower than in the human B-LCLs (Fig. 6B). These observations suggest that the block to HIV-1 in the 
marmoset B-LCLs occurs before or during integration.
2-LTR circles are a dead-end product formed only in the nucleus, so their presence is frequently used as an 
indicator of nuclear import. At 48 hours post-infection, the amount of 2-LTR circles in the marmoset B-LCLs 
was higher than in the human B-LCLs (Fig. 6C). These data suggest that the nuclear import of the preintegration 
complex was not blocked in the marmoset B-LCLs, consistent with the hypothesis that the HIV-1 block in B-LCLs 
was at the level of integration.
Some HIV-1 capsid mutants escape the post-entry block in marmoset B-LCLs. Some restriction 
factors targeting early events in the replication cycle, like TRIM5α and MX2, are known to specifically bind the 
viral capsid. We prepared a panel of HIV-1 capsid mutants that have been described previously to affect early 
events following virus entry33–39. We tested the ability of the capsid mutants to infect human and marmoset 
B-LCLs. The infectivity of the WT viruses in the marmoset B-LCLs was more than 10 times lower than in the 
human B-LCLs (Fig. 7A), in agreement with the results described above. Of interest, we observed that the cap-
sid mutants containing the N74D change, either alone or in combination with the V86M and/or H87Q capsid 
changes, exhibited increased infectivity (4.9- to 13.9-fold increase) in the marmoset B-LCLs compared to WT 
viruses (Fig. 7A). However, the combination of the N74D change with the Q50Y and T54Q changes was detri-
mental to the infectivity of the virus. Apparently, the N74D change in the capsid allows HIV-1 to escape the action 
of the factor responsible for the early post-entry block in the marmoset B cell lines. The V86M and H87Q capsid 
mutants also exhibited increased infectivity in the marmoset cells compared to WT viruses, although the escape 
was not as efficient as that of the N74D mutant.
To examine the mechanism of escape of the N74D capsid mutant in more detail, we studied the kinetics of 
the synthesis of reverse transcription products by real-time qPCR. The production by the N74D mutant of late 
reverse transcripts was higher in the marmoset B-LCLs compared to the human B-LCLs (Fig. 7B), as was the 
case for the WT virus (Fig. 6B). At early times post-infection, the N74D mutant showed a reduced capacity to 
synthesize late RT products compared to the WT virus in the marmoset B-LCLs (Figs 6B and 7B). However, at 
late time points after the infection (6/7 days), when all the remaining viral DNA should be integrated, the amount 
of proviral DNA in the marmoset cells was higher for the N74D mutant than for the WT virus (Fig. 7B, inset). 
These results agree with our observation that the marmoset B-LCLs were more permissive to the N74D mutant 
than to the WT HIV-1 virus. The N74D mutant exhibited reduced nuclear import (formation of 2-LTR circles) in 
human and marmoset B-LCLs (Fig. 7C), suggesting that the N74D mutant exhibited an advantage over the WT 
virus around the time of integration.
Characterization of the post-entry block to HIV-1 in marmoset B-LCLs. To assess if interferon- 
α ( IFN-α) plays a role in the post-entry block to HIV-1 in marmoset B-LCLs, we pretreated the cells with 500 U/ml 
of universal IFN-α for 24 h and then challenged them with VSV-G-pseudotyped HIV-1 luciferase reporter 
viruses. Treatment of human and marmoset B-LCLs with IFN-α significantly decreased the infectivity of WT 
HIV-1 (Fig. 8A). IFN-α treatment also decreased the infectivity of the escape mutant N74D (Fig. 8A). Apparently, 
IFN-α treatment results in a general decrease in HIV-1 infectivity in these B-LCLs. However, the decrease of 
infectivity observed in the marmoset B-LCLs for the N74D mutant was statistically less significant (p = 0.068), 
suggesting that in the marmoset cells this mutant was affected to a lesser degree by IFN-α treatment.
Previous studies have shown that treatment with As2O3 rescues retrovirus infectivity in cells expressing 
TRIM5α 40. This treatment has also been shown to suppress the antiviral activity of Lv4 and a post-entry inhibitory 
factor present in dendritic cells41,42. We analyzed the effect of As2O3 treatment on the infectivity of HIV-1 in the 
B-LCLs. The cells were preincubated with 4 μ M As2O3 for 3 hours and then challenged with VSV-G-pseudotyped 
HIV-1 luciferase reporter viruses. In the human B-LCLs, treatment with As2O3 significantly decreased the infec-
tivity of WT HIV-1 and the N74D mutant (Fig. 8B) by more than 10-fold and about 3-fold, respectively. On 
the contrary, in the marmoset B-LCLs, As2O3 treatment slightly increased the infectivity of HIV-1 WT as well 
as N74D mutant (Fig. 8B). Thus, in the presence of As2O3, HIV-1 infectivity is at least as great in the marmoset 
B-LCLs as in the human B-LCLs.
Discussion
Here we identify and characterize two post-entry blocks operative against HIV-1 that are present in common 
marmoset lymphocytes. These blocks appear to be effective regardless of the entry pathway used by the virus 
(Figs 1 and 2). Infections of heterokaryons (Fig. 3) suggest that both blocks are attributable to the presence of 
dominant-acting factor(s) that inhibit HIV-1 replication in these cells.
To date, a few dominant blocks to the early phase of lentivirus infection have been described in cells of differ-
ent species: Lv1 (later identified as TRIM5α ), Lv2, Lv3, Lv4, SAMHD1 and MX22–6,9,12,22,42–44. The identity of the 
factors responsible for the Lv2, Lv3 and Lv4 activities are currently unknown. TRIM5α acts at an early post-entry 
step in the viral life cycle, inducing premature uncoating of the capsid and reducing the formation of early and 
late reverse transcription products9,11. The first barrier to HIV-1 that we describe here is present in primary 
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lymphocytes isolated from the peripheral blood of common marmosets and, like TRIM5α and TRIMCyp, dis-
rupts the formation of viral reverse transcripts. However, our data failed to implicate either TRIM5α or TRIMCyp 
in this block in common marmoset cells (Fig. 5A and B). This block is also phenotypically distinct from those 
instituted by other previously described dominant-acting factors, such as MX2, Lv2, Lv3 or Lv4. SAMHD1 has 
Figure 7. Infectivity of HIV-1 capsid mutants in B-LCLs. (A) Human (hu) or marmoset (mar) B-LCLs 
were challenged with single-cycle HIV-1 luciferase reporter viruses pseudotyped with VSV-G and containing 
the indicated changes in their capsids. Forty-eight hours later, the infectivity of the viruses was determined 
by measuring the relative luciferase activity (RLU) in the cells. The results of three or five independent 
experiments and their means are shown. The mean fold change in infectivity for each mutant relative to WT 
virus in the marmoset B-LCLs is shown above the chart. NI, non-infected. (B,C) Human (hu) or marmoset 
(mar) B-LCLs were challenged with the single-cycle HIV-1 N74D capsid mutant as in the experiments shown 
in Fig. 6A,B and C. At different time points after infection, cells were collected and total DNA isolated. The 
amounts of late RT products (B) and 2-LTR circles (C) were quantified by real-time qPCR using TaqMan® 
chemistry. The results of two independent experiments are shown. The inserts in panel B show the amount of 
viral cDNA six (left) or seven (right) days post-infection (integrated proviruses) for the WT and N74D viruses. 
ND, not detectable.
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also been reported to block lentiviruses at an early post-entry step, blocking reverse transcription by depleting 
the dNTP pool in cells of the myeloid lineage and quiescent CD4+ T lymphocytes3,5,45,46. However, SAMHD1 has 
been shown to be inactive due to phosphorylation in activated T lymphocytes47,48; as our marmoset PBLs are acti-
vated, SAMHD1 seems an unlikely candidate for the observed block. Together, our results suggest the presence 
of a novel dominant-acting restriction factor in common marmoset PBLs. Following the tradition for naming 
dominant-acting factors with anti-lentiviral activity of unknown identity, we suggest the name Lv5.
In marmoset B-LCLs, we detected the presence of another early phase block to HIV-1. In contrast to the block 
observed in marmoset PBLs, the synthesis of HIV-1 reverse transcription products is an efficient process in the 
marmoset B-LCLs, even more so than in human B-LCLs (Fig. 6). The formation of 2-LTR circles also occurs 
Figure 8. Characterization of the post-entry block to HIV-1 in B-LCLs. Human (hu) or marmoset (mar) 
B-LCLs were challenged with single-cycle HIV-1 WT or N74D capsid mutant luciferase reporter viruses 
pseudotyped with VSV-G. (A) Cells were pre-treated with 500 U/ml of universal IFN-α for 24 hours before the 
infection. (B) Cells were pre-treated with 4 μ M As2O3 for 3 hours before the infection. The cells were maintained 
in the presence of the treatment for 24 hours after the viral challenge. Forty-eight hours post-challenge, the 
infectivity of the viruses was determined by measuring the relative luciferase activity (RLU) in the cells. The 
results of five independent experiments are shown. Reported p-values (2-tailed) were obtained with a paired 
t-test (untreated versus treated cells). NT, no treatment.
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normally in these cell lines, indicating that the factor responsible for this second block likely acts after nuclear 
import and before or during integration of the viral DNA (Fig. 6). Thus, the factor responsible for the marmo-
set B-LCL block probably exerts its action in the nucleus. The mechanism of action of this factor resembles the 
recently reported Lv4 activity that blocks viruses of the SIVmac/SIVsm/HIV-2 lineage in human blood cells42. In that 
work, Pizzato and colleagues also showed that the Lv4 activity targets the capsid of SIVmac, SIVsm, and HIV-2. In 
our study, we found that the N74D and, to a lesser degree, the V86M and H87Q capsid mutants escape the block 
present in marmoset B-LCLs (Fig. 7A). This observation suggests that the factor responsible for this anti-HIV-1 
activity might either directly target the capsid or be influenced by a capsid-specified process. Lentiviruses like 
HIV-1 are able to infect non-dividing cells and have evolved strategies to enter the nucleus through the nuclear 
pore complex (NPC). The molecular mechanism by which HIV-1 pre-integration complexes (PICs) traverse the 
NPC is under active investigation. The role of CA in nuclear import has been highlighted by several studies. 
Although for reverse transcription to occur, a partial uncoating of the viral capsid is necessary, different studies 
suggest that significant amounts of CA remain in the preintegration complex (PIC) and are probably translocated 
into the nucleus49–52. HIV-1 has been shown to mainly interact with NUP358/RANBP2, NUP153 and TNPO3 
to enter the nucleus53,54. However, the N74D mutant seems to be less sensitive to TNPO3 and Nup358/RANBP2 
depletion and instead uses different nucleoporins like NUP155 to enter the nucleus32. A truncated form of CPSF6 
that is expressed in the cytoplasm has been identified as a potent inhibitor of HIV-1 that blocks nuclear import 
of the PIC32. HIV-1 harboring the N74D capsid change fails to interact with CPSF6 and evades this nuclear 
import restriction32. It is unlikely that marmoset CPSF6 factor is responsible for the post-entry block in marmoset 
B-LCLs, as nuclear import appears to be unaffected. In addition, there is 100% identity between marmoset and 
human CPSF6. The N74D mutant has been shown to enter the nucleus though an altered nuclear entry pathway 
that results in integration in genomic regions that are sparse in transcription units compared to WT viruses that 
integrate in gene-rich chromosomal regions55,56. Thus, the use of a different nuclear entry pathway by the N74D 
mutant might contribute to the escape from the Lv4-like activity in the marmoset B-LCLs. One model is that the 
factor responsible for the Lv4 anti-viral activity might be associated with gene-rich regions of the chromosomes.
Arsenic trioxide treatment has been shown to suppress the antiviral activity of TRIM5α , Lv4, and a post-entry 
inhibitory factor present in dendritic cells (DC)40–42. We found that treatment with arsenic specifically increased 
the infectivity of HIV-1 in the marmoset B-LCLs, whereas HIV-1 infectivity decreased in the human B-LCLs; 
the observed decrease in the human B-LCLs may have possibly resulted from non-specific toxic effects of the 
treatment. The mechanism by which arsenic trioxide relieves the restriction by TRIM5α , Lv4, or the DC factor 
is unknown. Arsenic could be targeting a common cofactor needed for all three restrictions, or it may be acting 
via a different mechanism in each case. Arsenic has been implicated in several cellular pathways like DNA repair 
inhibition, cell cycle disruption and ubiquitin dysregulation57. Trivalent arsenic has been shown to selectively 
interact with DNA repair proteins containing zinc finger motifs with at least 3 cysteine residues58. Such proteins 
would be expected to reside in the nucleus and could be candidates for the restriction factor in marmoset B-LCLs.
In summary, we have demonstrated the existence of two post-entry blocks in marmoset lymphocytes. The first 
block (Lv5) is found in primary lymphocytes and acts at the level of reverse transcription. The second (Lv4-like) 
is present in a B cell line and blocks HIV-1 infection at the level of viral DNA integration. Our data leave open the 
possibility that the Lv4-like block is also present in primary marmoset lymphocytes. Identification of the factors 
responsible for the Lv4-like and Lv5 activity and elucidation of their molecular mechanism of action could assist 
understanding of the early phase of HIV-1 infection and the development of interventions.
Materials and Methods
Cell lines and reagents. 293T cells were obtained from the American Type Culture Collection and main-
tained in DMEM supplemented with 10% fetal bovine serum (DMEM-10). The human and common marmoset 
B-LCLs were obtained from the Coriell Institute for Medical Research (cat# GM00607 and GM07404, respec-
tively) and maintained in RPMI1640 supplemented with 10% fetal bovine serum (RPMI-10).
Peripheral blood lymphocytes. Peripheral blood lymphocytes (PBLs) were isolated from whole blood 
samples using Ficoll-Paque Plus gradients according to the manufacturer’s instructions. After isolation, the cells 
were activated for 3 days with 1 μ g/ml of phytohemagglutinin P and cultured in complete lymphocyte medium 
(RPMI1640 supplemented with 20% fetal bovine serum, 10% IL-2 (Hemagen), 25 mM HEPES, 2 mM glutamine 
and antibiotics). The adherent cells were discarded. As the amount of blood that we can obtain from marmosets 
is limited, the activated PBLs (human, marmoset and rhesus) were generally grown for a few days in complete 
lymphocyte medium to obtain sufficient cells for the infection experiments.
Human fresh whole blood samples were obtained from healthy anonymous volunteers through Research 
Blood Components, LLC (Boston, MA, USA) or the Transfusion Center of the Community of Madrid (Spain). 
Proper informed consent was obtained from each donor according to local regulations.
Common marmoset and rhesus macaque blood samples were obtained from the New England Primate 
Research Center or the German Primate Center. For some experiments, frozen marmoset peripheral blood mon-
onuclear cells were obtained from the Netherlands Biomedical Primate Research Center.
Viruses. HIV-1 and SIVmac single-cycle luciferase or GFP reporter viruses were prepared by transfection of 
293T cells by the calcium phosphate method. The plasmids used for preparation of the viruses were: the pCMVΔ 
P1Δ envpA packaging plasmid, a Rev-expressing plasmid and pHIvec2.luc or pHIvec2.GFP vectors for HIV-159,60, 
or pSIV1.GFP or pSIvec1.luc plus a Rev-expressing plasmid for SIVmac59. All viruses were pseudotyped with the 
VSV-G envelope glycoprotein by cotransfecting with a pHCMV plasmid expressing VSV-G.
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Forty-eight hours after transfection, supernatants containing reporter viruses were harvested and cleared by 
low-speed centrifugation. The amount of virus in the supernatants was quantified by measuring reverse tran-
scriptase activity.
Single-cycle infectivity assay. The efficiency of a single cycle of HIV-1 or SIVmac infection was measured 
by using recombinant reporter viruses expressing firefly luciferase and pseudotyped with VSV-G or A-MLV enve-
lope glycoproteins.
Cells were seeded at a density of 105 (for the B-LCLs) or 5 × 105 (for the PBLs) cells/well in 96-well luminometer- 
compatible tissue culture plates. The cells were challenged with 10,000 (for the B-LCLs) or 50,000 (for the PBLs) 
reverse transcriptase units (cpm) of viruses in a total volume of 100 μ l. Forty-eight hours later, the medium was 
removed and cells were lysed with 30 μ l of passive lysis buffer (Promega). Luciferase activity was measured using 
an EG&G Berthold LB 96 V microplate luminometer or a BMG Labtech FLUOstar Optima microplate reader.
Heterokaryon assay. Equal amounts of human or marmoset PBLs or B-LCLs were mixed and fused by 
treatment with polyethylene glycol 1500 (PEG1500) (Roche) according to the manufacturer’s instructions. 
Control cell mixtures were treated according to the same protocol except that buffer (75 mM Hepes pH 7.5) was 
substituted for PEG1500. After fusion, the cells were resuspended in medium and plated in 96-well plates compat-
ible with luminescence. After about 3 hours of recovery, the cells were challenged with HIV-1 luciferase reporter 
viruses pseudotyped with VSV-G. The level of infectivity was determined forty-eight hours later by measuring 
the luciferase activity in the cells.
Analysis of reverse transcription products by real-time qPCR. The viral stocks used for the infec-
tions were pretreated with 20 U/ml of DpnI (New England Biolabs) or 10 U/ml of DNase I (Promega) for 1 h at 
37 °C to eliminate plasmid DNA that might be present in the viral preparation. Six million human and marmoset 
PBLs or B-LCLs were challenged with 800,000 (for the PBLs) or 450,000 (for the B-LCLs) reverse transcriptase 
units (cpm) of VSV-G-pseudotyped HIV-1 GFP reporter viruses in a total volume of 500 μ l. As a control, cells 
were transduced in parallel with viruses lacking the VSV-G envelope glycoprotein. Two hours after transduction, 
the cells were washed 3 times with phosphate buffered saline (PBS) to eliminate excess virus and resuspended 
in 3 ml of medium. At different times post-infection, an aliquot containing ~106 cells was collected to isolate the 
total DNA. The formation of early and late reverse transcription products and 2-LTR circles was measured by 
real-time qPCR, as previously described22,31.
Ethical statement. Human fresh whole blood samples used in this study were obtained from healthy anon-
ymous volunteers through Research Blood Components, LLC (Boston, MA, USA) or the Transfusion Center of 
the Community of Madrid (Spain). Research Blood Components follows American Association of Blood Banks 
guidelines for drawing donors. The Transfusion Center of the Community of Madrid follows the Spanish leg-
islation on blood banks to collect samples from donors. In all cases, an Institutional Review Board approved 
informed consent for drawing the blood samples was obtained from each donor according to local regulations. 
Confidentiality and lack of donor identification was assured. The usage of human blood samples for this study 
from these sources was approved by the Dana-Farber Cancer Institute Office for Human Research Studies and 
the joint Ethics Committee for Research at Centro de Biología Molecular “Severo Ochoa” and Centro Nacional 
de Biotecnología, respectively.
Blood samples from common marmosets and rhesus macaques were used in this work to study the blocks to 
HIV-1 replication present in these monkeys. Animals were housed at the New England Primate Research Center, 
the German Primate Center or the Netherland Biomedical Primate Research Center.
Animals at the New England Primate Research Center were cared for according to the standards of the 
Association for Assessment and Accreditation of Laboratory Animal Care and the Harvard Medical School 
Animal Care and Use Committee. Blood collection and procedures on animals at the New England Primate 
Research Center were approved by the Harvard Medical Area (HMA) Standing Committee on Animals (proto-
col number 04789) and were in compliance with the Animal Welfare Act and the Public Health Service Policy 
on Humane Care and Use of Laboratory Animals. The HMA Standing Committee on Animals has an approved 
Animal Welfare Assurance on file (A3431-01) with the Office for Laboratory Animal Welfare.
Care of and all procedures on the animals performed at the German Primate Center and the Netherlands 
Biomedical Primate Research Center (BPRC) were done according to local legislation, the European Union 
Directive 2010/63/EU on the protection of animals used for scientific purposes and the EU recommendations 
2007/526/EG for the accommodation and care of animals used for experimental and other scientific purposes. 
The German Primate Center is registered and authorized by the local and regional veterinary government author-
ities (reference number 32.22/VO Stadt Göttingen; 392001/7 Stadt Göttingen). Consultation with the Institutional 
Animal Care and Use Committee (IACUC) is documented under Ethics no. 2–16. Blood sampling of common 
marmosets at the BPRC was approved by the independent Animal Ethics Committee of the BPRC (Approval #730). 
The BPRC is AAALAC accredited.
For this study, only non-surgical collection of blood was needed. No other procedures were carried out on the 
animals for this study. For the phlebotomy, animals were sedated with ketamine HCl (10–50 mg/kg, IM) or with 
telazol (4–10 mg/kg, IM) to reduce pain and discomfort. The phlebotomy site was prepped with alcohol. Blood 
samples were obtained from a peripheral vein. The amount of blood collected from any animal as a single sample 
in a 2-week period did not exceed 10% of the circulating blood volume.
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The common marmosets utilized in this study were socially housed. The rhesus macaques were socially 
housed unless they were being conditioned for other studies or were scheduled for return to the breeding colony. 
Compensatory enrichment was provided to animals that were not socially housed.
Statistical analyses. Each experiment was repeated at least twice. The statistical analyses were carried out, 
when appropriate, with the Excel program. The significance levels (alpha) were set at 0.05. The p values were cal-
culated with a two-tailed t-test. When the equal variance test performed with SigmaPlot failed, the p values were 
calculated with the unequal variance two-tailed t-test option provided in the Excel program. A Shapiro-Wilk test 
was performed in all cases to confirm the normality of the data using the SigmaPlot program.
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